Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions.

Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions.
Gastrointest Endosc Clin N Am. 2020 Jul;30(3):553-568
Authors: Kisiel JB, Eckmann JD, Limburg PJ
Abstract
After 2 screen-setting studies showing high sensitivity for colorectal cancer and advanced precancerous lesions, multitarget stool DNA testing was endorsed by the US Preventative Services Task Force as a first-line colorectal cancer screening test. Uptake has increased exponentially since approval by the US Food and Drug Administration and Centers for Medicare and Medicaid Services. Adherence to testing is approximately 70%. Patients with positive results have high diagnostic colonoscopy completion rates in single-center studies. The positive predictive value for colorectal neoplasia in postapproval studies is high. Next-generation test prototypes show promise to extend specificity gains while maintaining high sensitivity.
PMID: 32439088 [PubMed - in process]

Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Kisiel JB, Eckmann JD, Limburg PJ Tags: Gastrointest Endosc Clin N Am Source Type: research